Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

Described herein is a drug product delivery device and method of delivering a drug on a swab. The drug product delivery device may include an applicator platform housed within a rigid housing. The applicator platform may be in the form of a plunger. One or more fluidic channels carry fluid from a storage chamber to an applicator. A frangible seal is attached to the plunger between the storage chamber and the applicator. The frangible seal blocks the fluid from moving from the storage chamber into one or more fluidic channels. Actuation of the plunger causes the frangible seal to be ruptured, which causes the fluid to exit the fluid storage chamber and enter into the one or more fluidic channels. The one or more fluidic channels carry the fluid to the applicator.

Described herein is a drug product delivery device and method of delivering a drug on a swab. The drug product delivery device may include an applicator platform housed within a rigid housing. The applicator platform may be in the form of a plunger. One or more fluidic channels carry fluid from a storage chamber to an applicator. A frangible seal is attached to the plunger between the storage chamber and the applicator. The frangible seal blocks the fluid from moving from the storage chamber into one or more fluidic channels. Actuation of the plunger causes the frangible seal to be ruptured, which causes the fluid to exit the fluid storage chamber and enter into the one or more fluidic channels. The one or more fluidic channels carry the fluid to the applicator.

The present disclosure relates to microneedle devices and methods for treating a disease (for example, diabetes) using a degradable cross-linked gel for self-regulated delivery of a therapeutic agent (for example, insulin).

The present disclosure relates to microneedle devices and methods for treating a disease (for example, diabetes) using a degradable cross-linked gel for self-regulated delivery of a therapeutic agent (for example, insulin).

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.

Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.

Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.